SQZ Biotech completes oversubscribed $72M Series C

posted in: News | 0

SQZ Biotech completes oversubscribed $72M Series C

SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced the completion of an oversubscribed $72 million Series C financing. New investors include Everblue, Illumina Ventures, Invus, Orient Life, and Viva Ventures Biotech Group. Existing investors also participated and include Bridger Healthcare Partners, Global Health Science Fund, GV, JDRF T1D Fund, NanoDimension, and Polaris.

“We are deeply appreciative of the excitement and support investors have expressed for the SQZ vision,” said Armon Sharei, PhD, SQZ’s co-founder and CEO. “Our cell therapy platform has transformative potential and with this funding, we have the financial strength to drive our programs in solid tumors and autoimmune diseases to the clinic, taking us closer to our goal of bringing high impact cell therapies to patients in need.”

The SQZ platform directly engineers complex cell functions without affecting cell health, with a simple and scalable process. The therapeutic platform can bring cell therapies into indications where new and innovative treatments are needed the most.

Proceeds from the financing support SQZ’s most advanced programs in solid tumors and auto-immunity. These first applications focus on SQZ’s unique potential to generate target-specific immune responses in patients through natural mechanisms. The Company’s lead program in antigen presenting cells (APCs) for oncology will have its first application in multiple HPV+ tumor indications; future applications will address solid tumors across cancer types. SQZ’s APCs are engineered to deliver tumor-associated antigens that aim to prime and activate a patient’s endogenous killer T cells against the target of choice in order to infiltrate tumors and destroy them. The Company’s immune tolerance programs aim to leverage similar mechanisms to shut down target-specific immune responses. SQZ is currently pursuing type 1 diabetes and other autoimmune indications.

Press Release